Show simple item record

AuthorThirumal Kumar, D
AuthorJain, Nikita
AuthorS, Udhaya Kumar
AuthorGeorgePriya Doss, C
AuthorZayed, Hatem
Available date2019-12-30T07:07:26Z
Publication Date2019-12
Publication NameJournal of Biomolecular Structure and Dynamicsen_US
CitationThirumal Kumar, Nikita Jain, Udhaya Kumar S, C GeorgePriya Doss & Hatem Zayed (2019): Identification of potential inhibitors against pathogenic missense mutations of PMM2 using a structure-based virtual screening approach, Journal of Biomolecular Structure and Dynamics, DOI: 10.1080/07391102.2019.1708797
AbstractThe autosomal recessive phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) is characterized by defective functioning of the PMM2 enzyme, which is necessary for the conversion of mannose-6-phosphate into mannose-1-phosphate. Here, a computational pipeline was drawn to identify the most significant mutations, and further, we used a virtual screening approach to identify a new lead compound to treat the identified significant mutations. We searched for missense mutation data related to PMM2-CDG in HGMD®, UniProt, and ClinVar. Our search yielded a total of 103 mutations, of which 91 are missense mutations. The D65Y, I132N, I132T, and F183S mutations were classified as deleterious, destabilizing, and altering the biophysical properties using the PredictSNP, iStable, and Align GVGD prediction tools. Additionally, we applied a multistep protocol to screen for an alternative lead compound to the existing CID2876053 (1-(3-chlorophenyl)-3,3-bis(pyridine-2-yl)urea) with affinity to these identified significant mutants. Two compounds, CHEMBL1491007 (6-chloro-4-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)-1H-quinolin-2-one) and CHEMBL3653029 (5-chloro-4-[6-[(3-fluorophenyl)methylamino]pyridin-2-yl]-N-(piperidin-4-ylmethyl)pyridin-2-amine), exhibited the highest binding affinity with the selected mutants and were chosen for further analysis. Through molecular docking, molecular dynamics simulation, and MMPBSA analysis, we found that the known compound, i.e., CID2876053, has stronger interaction with the D65Y mutant. The newly identified lead compound CHEMBL1491007 showed stronger interaction with the I132N and I132T mutants, whereas the most deleterious mutant, F183S, showed stronger interaction with CHEMBL3653029. This study is expected to aid in the field of precision medicine, and further to and analysis of these lead compounds might shed light on the treatment of PMM2-CDG.
PublisherTaylor & Francis
Subjectmolecular dynamics
Subjectvariant classification
Subjectvirtual screening
TitleIdentification of potential inhibitors against pathogenic missense mutations of PMM2 using a structure-based virtual screening approach.

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record